drugset / Trial / NCT07653100
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Timeline
- Start
- 2026-06-22
- Primary completion
- 2027-01-25
- Completion
- 2027-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RSVpreF | Vaccine | — | — |